Arrowhead Pharma doses first subjects in phase 1/2a study of ARO-MAPT to treat Alzheimer’s disease and other tauopathies: Pasadena, California Thursday, December 11, 2025, 12:00 ...

Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being ...

This article explores how challenges such as sequence optimization, immune activation and off-target effects are being ...

Tanshinones are major bioactive components in Salvia miltiorrhiza and are widely used in cardiovascular therapies. However, ...

In November 2025, Epicrispr Biotechnologies Inc. announced a clinical trial is to learn how safe and tolerable EPI-321 is and ...

Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the presentation of preclinical ...

Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...

Acute myeloid leukemia (AML) is a malignancy characterized by the clonal proliferation of myeloid hematopoietic progenitor or stem cells, primarily ...

Guiyang’s high-level pesticide forum spotlights next-gen technologies, global insights, and green innovation accelerating ...

Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have captured the first detailed molecular ...

A research team at Florida State University's Institute of Molecular Biophysics and Department of Chemistry and Biochemistry ...

Viruses are typically described as tiny, perfectly geometric shells that pack genetic material with mathematical precision, ...